Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug small molecule |
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2011 |
| gptkbp:ATCCode |
L01XE16
|
| gptkbp:bioavailability |
43%
|
| gptkbp:brand |
gptkb:Xalkori
|
| gptkbp:CASNumber |
877399-52-5
|
| gptkbp:contraindication |
hypersensitivity to crizotinib
|
| gptkbp:discoveredBy |
gptkb:Pfizer
|
| gptkbp:hasMolecularFormula |
C21H22Cl2FN5O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Crizotinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea edema constipation fatigue vision disorder |
| gptkbp:target |
gptkb:ALK
gptkb:MET ROS1 |
| gptkbp:usedFor |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:bfsParent |
gptkb:Non-Small_Cell_Lung_Cancer
|
| gptkbp:bfsLayer |
6
|